Close Menu

NEW YORK (GenomeWeb) – Following yesterday's simultaneous approval of Foundation Medicine's FoundationOne CDx test as a companion diagnostic for solid tumors by the US Food and Drug Administration and a preliminary national coverage determination (NCD) by the Centers for Medicare and Medicaid Services, company executives today provided additional comment on the implications of the decisions for the firm's business.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.